Matisse Pharmaceuticals
Matisse Pharmaceuticals BV is a biopharmaceutical clinical stage company dedicated to developing safe and innovative therapies for disease indications characterized by elevated levels of extracellular cytotoxic histones, such as in sepsis and septic shock. Their mission is to save millions of lives by effectively neutralizing extracellular cytotoxic histones, aiming to become the first company worldwide to effectively combat sepsis. The company focuses on life-threatening inflammation and has a product portfolio centered around the development of M6229, a treatment targeting sepsis and septic shock. They collaborate with leading research institutions and have a strategic network of partners to accelerate their development efforts.
Industries
Nr. of Employees
small (1-50)
Matisse Pharmaceuticals
Burgemeester Lemmensstraat 352, 6160 BC Geleen, The Netherlands
Products
Heparin‑derived low‑anticoagulant therapeutic (lead compound)
A negatively charged, low-anticoagulant fraction derived from heparin designed to bind and neutralize extracellular cationic histones; developed for intravenous administration in sepsis and septic shock.
Histone-detection in vitro diagnostic (LC-MS) — companion diagnostic
An LC-MS based in vitro diagnostic assay for detection and quantification of circulating histones to identify patients likely to benefit from the therapeutic.
Heparin‑derived low‑anticoagulant therapeutic (lead compound)
A negatively charged, low-anticoagulant fraction derived from heparin designed to bind and neutralize extracellular cationic histones; developed for intravenous administration in sepsis and septic shock.
Histone-detection in vitro diagnostic (LC-MS) — companion diagnostic
An LC-MS based in vitro diagnostic assay for detection and quantification of circulating histones to identify patients likely to benefit from the therapeutic.
Services
Partnership-based project collaboration with academic and industry partners to advance preclinical research, clinical trials and diagnostic development.
Coordination and management of drug substance process development, formulation, analytics, IMP manufacturing and regulatory CMC activities via external service providers.
Partnership-based project collaboration with academic and industry partners to advance preclinical research, clinical trials and diagnostic development.
Coordination and management of drug substance process development, formulation, analytics, IMP manufacturing and regulatory CMC activities via external service providers.
Expertise Areas
- Clinical trial management
- CMC development and GMP manufacturing
- Biomarker and companion diagnostic development
- Preclinical pharmacology and multi-species efficacy testing
Key Technologies
- Affinity chromatography fractionation
- Low-anticoagulant heparin-derived therapeutic chemistry
- Intravenous infusion therapeutics
- LC-MS (liquid chromatography–mass spectrometry) biomarker assays
News & Updates
Matisse Pharmaceuticals B.V. received approval from the German regulatory authorities (BfArM) to start a phase 1 study evaluating the safety, tolerability, and pharmacokinetics of a prolonged intravenous infusion of M6229 in healthy volunteers. The study aims to assess the safety and pharmacodynamics of extended dosing in sepsis treatment.
The phase I/IIa clinical dose escalation study with M6229 in septic patients in ICU setting successfully met its primary objectives, showing favorable safety, tolerability, and pharmacokinetics. The study also indicated a pharmacodynamic effect on plasma histones and a decrease in SOFA scores, supporting further development of M6229.
The company secured EUR 3.6 million from existing and new investors, including Brightlands Venture Partners, to continue preparations for a large-scale phase II study in sepsis patients, scale up production, and advance R&D projects.
Marcel Jacobs, with a background in biotech and business development, was appointed as CEO in January 2024 to lead the company's strategic growth and development efforts.
Prof. Carolyn Calfee, an expert in critical care and sepsis, was appointed to strengthen the scientific advisory board, bringing extensive experience in respiratory infections and sepsis research.
The company successfully completed the second cohort and is initiating the third dose level in a clinical trial assessing safety, tolerability, and pharmacodynamics of M6229 in septic ICU patients.
Matisse Pharmaceuticals B.V. received approval from the German regulatory authorities (BfArM) to start a phase 1 study evaluating the safety, tolerability, and pharmacokinetics of a prolonged intravenous infusion of M6229 in healthy volunteers. The study aims to assess the safety and pharmacodynamics of extended dosing in sepsis treatment.
The phase I/IIa clinical dose escalation study with M6229 in septic patients in ICU setting successfully met its primary objectives, showing favorable safety, tolerability, and pharmacokinetics. The study also indicated a pharmacodynamic effect on plasma histones and a decrease in SOFA scores, supporting further development of M6229.
The company secured EUR 3.6 million from existing and new investors, including Brightlands Venture Partners, to continue preparations for a large-scale phase II study in sepsis patients, scale up production, and advance R&D projects.
Marcel Jacobs, with a background in biotech and business development, was appointed as CEO in January 2024 to lead the company's strategic growth and development efforts.
Prof. Carolyn Calfee, an expert in critical care and sepsis, was appointed to strengthen the scientific advisory board, bringing extensive experience in respiratory infections and sepsis research.
The company successfully completed the second cohort and is initiating the third dose level in a clinical trial assessing safety, tolerability, and pharmacodynamics of M6229 in septic ICU patients.